Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Completion of the Acquisition of Quotient Diagnostics Limited,

Director's Dealing and Total Voting Rights

Completion of the Acquisition of Quotient Diagnostics Limited

EKF Diagnostics Holdings plc (AIM: EKF), which has recently refocused on the in-vitro diagnostic devices market, announces that it has today completed the acquisition of the entire issued share capital of Quotient Diagnostics Limited ("Quotient").

The 15,507,153 new ordinary shares in the Company which were issued to satisfy the initial consideration for Quotient were admitted to trading on AIM at 8.00 a.m. this morning.

Directors' Dealing

Following the issue of the new ordinary shares, David Evans, Executive Chairman of the Company, now holds a total of 1,279,288 ordinary shares in the Company representing approximately 0.81 per cent. of the issued share capital.

Total Voting Rights

In accordance with the Financial Services Authority's Disclosure and Transparency Rules, EKF advises that, following the admission of the new ordinary shares, as at the date of this announcement it has a single class of shares in issue which are admitted to trading on AIM being ordinary shares and that there are 157,934,459 ordinary shares in issue, each carrying one vote per ordinary share. The Company does not hold any ordinary shares in treasury.

The total number of voting rights in the Company's ordinary shares is 157,934,459 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

Enquiries: